The Safety of Pimavanserin for Parkinson s Disease and Efforts to Reduce Antipsychotics for People With Dementia
psychiatryonline.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from psychiatryonline.org Daily Mail and Mail on Sunday newspapers.
Die PURE ZONE-schutzfolie Wirkt Zu 97 % Gegen SARS-coV-2*, Den Virusstamm, Der Covid-19 Verursacht*
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the promotion of Chief Scientific Officer Trevor Hallam, Ph.D., to President of Research. Dr. Hallam will also continue his role as Chief Scientific Officer. Since joining Sutro as CSO more than 10 years ago, Trevor has been instrumental in the development of our cell-free protein synthesis platform from a novel but immature technology to a robust multi-modality platform with a proven manufacturing capability. Additionally, Trevor conceived of and drove our vision to initially focus the platform on antibody drug conjugates (ADCs). Using Sutro s platform for ADCs captures the advantages and power of our proprietary cell-fre